Valuation : Colinz Laboratories Limited

Market Cap 18Cr 19.36L 16.66L 15.67L 14.32L 26.78L 26.86L 1.85Cr 71.87L 9.38Cr 72.7L 71.11L 30Cr P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 10Cr 10.74L 9L 9L 8L 14.86L 14.9L 1.03Cr 39.87L 5.2Cr 40.33L 39.45L 17Cr EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.44%
Yield 2025 *
-
Yield 2026 -
30/07 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
25/05 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
29/04 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
24/01 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
17/01 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
27/11 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
08/11 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
03/11 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/25/31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/25/21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/25/16 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
1 day+1.48%
1 week-1.95%
Current month+1.24%
1 month-11.19%
3 months+17.70%
6 months+64.87%
Current year+35.30%
1 week 69.25
Extreme 69.25
74.99
1 month 68.89
Extreme 68.89
85.99
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 15.7
Extreme 15.7
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 74 26/11/1990
Director/Board Member 33 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%-1.95%+68.74%+73.88% 19.36L
-0.89%-1.09%+19.16%+67.77% 4.83TCr
-1.72%-1.15%+45.80%+117.34% 4.05TCr
-0.70%-2.70%-10.84%+11.79% 1.19TCr
-2.01%-5.96%+10.47%+76.64% 1.18TCr
+2.31%0.00%+26.67%+153.33% 935.93Cr
+0.08%-4.11%+24.83%+43.80% 749.58Cr
-1.67%-0.35%+41.04%-11.59% 737.27Cr
-0.89%-3.09%+18.78%+207.82% 728.46Cr
-0.16%-2.36%-46.14%+16.28% 518.68Cr
Average -0.42%-2.08%+19.85%+75.71% 1.49TCr
Weighted average by Cap. -0.95%-1.71%+22.87%+82.78%

Financials

2025 2026
Net sales 6.53Cr 7L 6L 6L 5L 10L 10L 66.14L 25.67L 3.35Cr 25.96L 25.4L 11Cr 6.14Cr 6L 6L 5L 5L 9L 9L 62.17L 24.13L 3.15Cr 24.4L 23.87L 10Cr
Net income 49.66L 52.6T 45.26T 42.58T 38.9T 72.77T 72.97T 5L 2L 25.48L 2L 2L 82.08L 51.45L 54.49T 46.89T 44.12T 40.3T 75.39T 75.6T 5L 2L 26.4L 2L 2L 85.04L
Net Debt -4.91Cr -5L -4L -4L -4L -7L -7L -49.74L -19.3L -2.52Cr -19.53L -19.1L -8.11Cr -8.14Cr -9L -7L -7L -6L -11.93L -11.96L -82.47L -32L -4.18Cr -32.37L -31.67L -13Cr
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
04/26/04 ₹72.56 +1.48% 47
03/26/03 ₹71.50 +2.72% 351
02/26/02 ₹69.61 -4.38% 2,216
01/26/01 ₹72.80 +1.58% 10
31/26/31 ₹71.67 -3.15% 1,448
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock